A Phase 2 interventional study of Roxadustat and Oral Iron in Dialysis and Anemia, sponsored by FibroGen. Completed at 7 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-10-01.
Sponsored by FibroGen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.
Among the 43 studies testing roxadustat in Anemia, this one is the 35th largest by enrollment, is one of 3 that started in 2011, is one of 8 in phase 2, and was the 5th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:
Kyntra Bio
Ages 18+
Tianjin Medical University General Hospital
Ages 18–80
roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 26 · Phase 4 7
First in 2006; this study’s year is marked. 3 started in 2011.
This study's enrollment of 60 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 154 across the 43 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under FibroGen, one of the names counted as Kyntra Bio. Under that name alone:
FibroGen is the lead sponsor of 39 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 14 (100%) have results posted.
21 studies in Anemia by Kyntra Bio: 1 open now, 1 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 21 studies in Anemia by Kyntra Bio, this one is the 18th largest by enrollment, is one of 3 that started in 2011, is one of 8 in phase 2, and was the 4th registered.
Kyntra Bio’s Anemia studies by the year they started, since 2006.
1 of the studies testing roxadustat in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies testing roxadustat in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kyntra Bio’s 21 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with end-stage renal disease who recently started dialysis.
Participants on hemodialysis (HD) will be randomized to 3 treatment arms (A, B, and C) of in a 1:1:1 ratio to receive no iron supplementation, oral iron supplementation, and IV iron supplementation, respectively, in addition to roxadustat. At the same time, participants on peritoneal dialysis (PD) will be enrolled into Arm D. Arm E will enroll either HD or PD participants, and is an optional, confirmatory/supplemental treatment arm with flexible dosing and flexible iron supplementation based on the evaluation of data from the previous 4 treatment arms.
Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low weight [40 to 60 kilograms {kg}], medium weight [>60 to 90 kg], and heavy weight [>90 to 140 kg] participants will receive 60, 100, and 140 milligrams [mg] roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 140, 200, and 300 mg for low, medium, and high weight participants, respectively) during Weeks 5 and 9, depending on the hemoglobin (Hb) level and rate of Hb rise in the previous 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally 3 times weekly (TIW) for 12 weeks.
Drug: Roxadustat
Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
Drug: Roxadustat · Drug: Oral Iron
Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with approximately 60 mg IV iron (ferric gluconate complex in sucrose injection \[for example, Ferrlecit®\] or equivalent) once a week for 12 weeks.
Drug: Roxadustat · Drug: IV Iron
Participants on PD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
Drug: Roxadustat · Drug: Oral Iron
Tiered, weight-based dosing per schedule specified in the arm.
Also known as: FG-4592
Administered per oral dose and schedule specified in the arm.
Administered per IV dose and schedule specified in the arm.
Maximum Change From Baseline in Hb During Weeks 3-13
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration. This outcome measure is derived from the maximum change from baseline during Weeks 3-13, without last observation carried forward (LOCF) imputation.
Time frame: Baseline, Weeks 3-13
Mean Change From Baseline in Hb During Weeks 2-5, 6-9, and 10-13
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
Time frame: Baseline, Weeks 2-5, 6-9, and 10-13
Number of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥11.0 g/dL
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
Time frame: Week 3 to 13
Number of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥10.0 g/dL
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
Time frame: Week 3 to 13
Number of Participants With a Hb Response, Defined as an Increase in Hb by ≥1.0 g/dL From Baseline, by Weeks 5, 9, and 13
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
Time frame: Weeks 5, 9, and 13
Number of Participants Who Achieved Maximum Hb During Weeks 3-13
Time frame: Weeks 3-13
Number of Participants With a Maximum Change From Baseline in Hb During Weeks 3-13
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration. The number of participants who fall within the following categories of maximum change are reported: \<1 g/dL, ≥1 g/dL, 1 to \<2 g/dL, 2 to \<3 g/dL, \>3 to \<4 g/dL, ≥4 g/dL.
Time frame: Baseline, Weeks 3-13
Median Time to Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline)
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
Time frame: Baseline up to Week 13
Weekly Dose at First Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline)
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
Time frame: Baseline up to Week 13
Number of Participants Requiring Dose Increase at Weeks 5 and 9
Number of participants requiring dose increase due to any reasons is reported.
Time frame: Weeks 5 and 9
Number of Participants Requiring Dose Reduction or Dose Discontinuation Due to Excessive Erythropoiesis
Number of participants requiring dose reduction or dose discontinuation due to excessive erythropoiesis is reported.
Time frame: Weeks 5 and 9
Change From Baseline in Ferritin at Week 13
Baseline was defined as the average of the last 2 values prior to the first dose administration.
Time frame: Baseline, Week 13
Change From Baseline in Transferrin Saturation (TSAT) at Week 13
Time frame: Baseline, Week 13
Change From Baseline in Reticulocyte Hemoglobin Content at Week 13
Time frame: Baseline, Week 13
Number of Participants With Mean Hb Values 11.0-13.0 g/dL at Weeks 6-9 and 10-13
Time frame: Weeks 6-9 and 10-13
Number of Participants With Mean Hb Values Within 11.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥11.0 g/dL and Change of Hb ≥1 g/dL
Time frame: Weeks 10-13
Number of Participants With Mean Hb Values Within 10.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥10.0 g/dL and Change of Hb ≥1 g/dL
Time frame: Weeks 10-13
Number of Participants With Mean Hb Values in Excess of 13.0 and 14.0 g/dL at Weeks 6-9 and 10-13
Time frame: Weeks 6-9 and 10-13
Number of Participants With Mean Hb Values <10.0 g/dL at Weeks 6-9 and 10-13
Time frame: Weeks 6-9 and 10-13
Number of Participants Requiring Rescue Treatment With an Erythropoiesis-Stimulating Agent (ESA), Red Blood Cells (RBC) Transfusion, or IV Iron (Excluding Arm C)
Number of participants requiring rescue treatment with an ESA, RBC transfusion, or IV Iron (Excluding Arm C) was reported.
Time frame: Baseline up to Week 13
Number of Participants Requiring Therapeutic Phlebotomy
Number of participants who required therapeutic phlebotomy due to TEAE of abnormal erythropoiesis is reported.
Time frame: Baseline up to Week 13
Number of Participants Withdrawn From the Study Due to Inadequate Efficacy
Number of participants withdrawn from the study due to inadequate efficacy is reported.
Time frame: Baseline up to Week 16
Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 9 and 13
The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The physical functioning subscore and vitality subscore are reported. The scores ranged from 0 (worst) to 100 (Best). Higher score indicated a better health state. Baseline is defined as the last non-missing value prior to the first dose administration.
Time frame: Baseline, Weeks 9 and 13
Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Total Score at Weeks 9 and 13
FACT-An is composed of 27 core items which assess participant's function in 4 domains and 20 anemia-related items, grouped into 5 subscales as follows: Physical well-being (PWB): 7 items; Social/family well-being (SWB): 7 items; Emotional well-being (EWB): 6 items; Functional well-being (FWB): 7 items; and Anemia: 20 items. All FACT-An items were rated as: 0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much. Each subscale score was the sum of scores for the items in the subscale. The FACT-An total score was the sum of all 5 subscale scores, ranging from 0 (worst) - 188 (best). Higher scores represented better quality of life. Baseline is defined as the last non-missing value prior to the first dose administration.
Time frame: Baseline, Weeks 9 and 13
Number of Participants With Potentially Clinically Significant Laboratory Tests
Criteria for the potential clinical significance included: bilirubin (µmol/L) \>1.5 \* upper limit of normal (ULN), potassium (mmol/L) \>1.2 \* ULN, neutrophils (\*10\^9/L) ≤1, protein (g/L) \>1.1 \* ULN, leukocytes (\*10\^9/L) ≤2.5 or ≥15.
Time frame: Baseline up to Week 16
Number of Participants With TEAEs
An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs were defined as any event that either began or worsened after the first administration of study drug and within 28 days of the last dose. A summary of other nonserious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Baseline up to Week 16
Participants on hemodialysis (HD) were randomized to one of the 3 arms A, B, or C in 1:1:1 ratio to receive roxadustat with either no, per oral (PO), or intravenous (IV) iron supplementation, respectively. Participants on peritoneal dialysis (PD) were enrolled into Arm D and received roxadustat with PO iron supplementation.
| Milestone | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Started | 24 | 12 | 12 | 12 |
| Efficacy evaluable (ee) population | 23 | 12 | 10 | 10 |
| Completed | 21 | 12 | 10 | 10 |
| Not completed | 3 | 0 | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Other than specified | 1 | 0 | 1 | 0 |
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration. This outcome measure is derived from the maximum change from baseline during Weeks 3-13, without last observation carried forward (LOCF) imputation.
| grams/deciliter (g/dL) | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Baseline | 8.1 ± 0.2 | 8.5 ± 0.3 | 8.4 ± 0.3 | 8.7 ± 0.2 |
| Change at Weeks 3-13 | 2.8 ± 0.2 | 3.5 ± 0.5 | 3.5 ± 0.4 | 3.3 ± 0.2 |
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
| g/dL | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Baseline | 8.1 ± 0.2 | 8.5 ± 0.3 | 8.4 ± 0.3 | 8.7 ± 0.2 |
| Change at Weeks 2-5 | 1.1 ± 0.1 | 1.1 ± 0.2 | 1.0 ± 0.2 | 0.8 ± 0.3 |
| Change at Weeks 6-9 | 2.0 ± 0.2 | 2.3 ± 0.4 | 2.0 ± 0.4 | 1.8 ± 0.4 |
| Change at Weeks 10-13 | 2.1 ± 0.2 | 2.7 ± 0.5 | 3.0 ± 0.4 | 2.4 ± 0.2 |
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Number of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥11.0 g/dL | 10 | 8 | 8 | 9 |
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Number of Participants Whose Maximum Hb Achieved During Treatment Was at Least 1.0 g/dL Increase From Baseline and Was ≥10.0 g/dL | 17 | 10 | 8 | 10 |
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Week 5 | 21 | 9 | 7 | 7 |
| Week 9 | 22 | 10 | 9 | 9 |
| Week 13 | 22 | 11 | 10 | 10 |
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| <10 g/dL | 6 | 1 | 2 | 0 |
| 10 to <11 g/dL | 7 | 3 | 0 | 1 |
| 11 to 13 g/dL | 10 | 5 | 5 | 9 |
| >13 to 14 g/dL | 0 | 1 | 3 | 0 |
| >14 g/dL | 0 | 2 | 0 | 0 |
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration. The number of participants who fall within the following categories of maximum change are reported: \<1 g/dL, ≥1 g/dL, 1 to \<2 g/dL, 2 to \<3 g/dL, \>3 to \<4 g/dL, ≥4 g/dL.
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| <1 g/dL | 1 | 1 | 0 | 0 |
| ≥1 g/dL | 22 | 11 | 10 | 10 |
| 1 to <2 g/dL | 4 | 2 | 2 | 0 |
| 2 to <3 g/dL | 9 | 2 | 0 | 5 |
| >3 to <4 g/dL | 7 | 2 | 4 | 3 |
| ≥4 g/dL | 2 | 5 | 4 | 2 |
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
| weeks | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Median Time to Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline) | 4.0 (3.0 to 4.0) | 4.0 (3.0 to 6.0) | 4.0 (3.0 to 6.0) | 4.0 (3.0 to 8.0) |
Baseline Hb was defined as the mean of the last 3 central laboratory Hb values prior to the first dose administration.
| mg/kg | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Weekly Dose at First Hb Response (Increase in Hb by ≥1.0 g/dL From Baseline) | 4.2 ± 0.5 | 4.2 ± 1.2 | 4.5 ± 1.4 | 4.3 ± 1.4 |
Number of participants requiring dose increase due to any reasons is reported.
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Week 5 | 2 | 3 | 2 | 4 |
| Week 9 | 8 | 5 | 3 | 5 |
Number of participants requiring dose reduction or dose discontinuation due to excessive erythropoiesis is reported.
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Dose reduced at Week 5 | 3 | 5 | 3 | 5 |
| Dose interrupted at Week 5 | 1 | 0 | 0 | 0 |
| Dose reduced at Week 9 | 1 | 0 | 3 | 0 |
| Dose interrupted at Week 9 | 1 | 0 | 0 | 1 |
Baseline was defined as the average of the last 2 values prior to the first dose administration.
| micrograms/liter (µg/L) | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Baseline | 156.4 ± 12.9 | 162.5 ± 30.8 | 182.0 ± 27.4 | 137.4 ± 27.0 |
| Change at Week 13 | -119.7 ± 12.2 | -51.1 ± 25.2 | -25.2 ± 33.5 | -65.1 ± 29.4 |
| percentage of transferrin | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Baseline | 18.8 ± 0.8 | 19.0 ± 1.0 | 18.1 ± 1.5 | 19.3 ± 1.8 |
| Change at Week 13 | -7.4 ± 1.4 | 2.6 ± 2.5 | 0.7 ± 2.9 | -1.6 ± 2.6 |
| picogram (pg) | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Baseline | 31.0 ± 0.3 | 31.6 ± 0.5 | 31.5 ± 0.5 | 30.4 ± 0.4 |
| Change at Week 13 | -2.2 ± 0.7 | -1.9 ± 0.9 | -1.0 ± 0.6 | -0.2 ± 0.6 |
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Weeks 6-9 | 6 | 5 | 4 | 5 |
| Weeks 10-13 | 5 | 2 | 5 | 7 |
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Number of Participants With Mean Hb Values Within 11.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥11.0 g/dL and Change of Hb ≥1 g/dL | 5 | 2 | 5 | 7 |
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Number of Participants With Mean Hb Values Within 10.0-13.0 g/dL During Weeks 10-13 Among Those With Maximum Hb ≥10.0 g/dL and Change of Hb ≥1 g/dL | 15 | 7 | 7 | 9 |
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Week 6-9 | 0 | 0 | 0 | 0 |
| Week 10-13 | 0 | 1 | 1 | 0 |
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Week 6-9 | 10 | 4 | 2 | 3 |
| Week 10-13 | 8 | 3 | 2 | 1 |
Number of participants requiring rescue treatment with an ESA, RBC transfusion, or IV Iron (Excluding Arm C) was reported.
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Blood transfusion for severe anemia | 0 | 0 | 1 | 0 |
| Blood transfusion for gastrointestinal bleeding | 1 | 0 | 0 | 0 |
| IV iron for acute iron deficiency | 1 | 0 | — | 0 |
| IV iron for a treatment-emergent adverse event (TEAE) of thrombocytosis | 1 | 0 | — | 0 |
Number of participants who required therapeutic phlebotomy due to TEAE of abnormal erythropoiesis is reported.
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Number of Participants Requiring Therapeutic Phlebotomy | 0 | 1 | 0 | 0 |
Number of participants withdrawn from the study due to inadequate efficacy is reported.
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Number of Participants Withdrawn From the Study Due to Inadequate Efficacy | 0 | 0 | 0 | 0 |
The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function, and vitality. The physical functioning subscore and vitality subscore are reported. The scores ranged from 0 (worst) to 100 (Best). Higher score indicated a better health state. Baseline is defined as the last non-missing value prior to the first dose administration.
| units on a scale | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Physical functioning subscore: Baseline | 38.8 ± 2.3 | 40.7 ± 3.2 | 41.2 ± 3.4 | 40.8 ± 1.8 |
| Physical functioning subscore: Change at Week 9 | 4.8 ± 1.6 | 1.6 ± 2.5 | 1.5 ± 2.5 | 3.4 ± 1.2 |
| Physical functioning subscore: Change at Week 13 | 5.2 ± 1.8 | 1.8 ± 2.1 | 4.8 ± 1.8 | 2.3 ± 1.3 |
| Vitality subscore: Baseline | 46.3 ± 2.2 | 48.2 ± 4.1 | 49.0 ± 3.5 | 46.8 ± 3.6 |
| Vitality subscore: Change at Week 9 | 2.9 ± 1.8 | -1.0 ± 4.0 | 3.4 ± 2.8 | 5.9 ± 3.0 |
| Vitality subscore: Change at Week 13 | 3.9 ± 1.7 | 1.6 ± 3.7 | 3.1 ± 2.3 | 6.2 ± 1.6 |
FACT-An is composed of 27 core items which assess participant's function in 4 domains and 20 anemia-related items, grouped into 5 subscales as follows: Physical well-being (PWB): 7 items; Social/family well-being (SWB): 7 items; Emotional well-being (EWB): 6 items; Functional well-being (FWB): 7 items; and Anemia: 20 items. All FACT-An items were rated as: 0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much. Each subscale score was the sum of scores for the items in the subscale. The FACT-An total score was the sum of all 5 subscale scores, ranging from 0 (worst) - 188 (best). Higher scores represented better quality of life. Baseline is defined as the last non-missing value prior to the first dose administration.
| units on a scale | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Baseline | 123.5 ± 6.8 | 118.9 ± 10.9 | 128.8 ± 11.3 | 122.8 ± 7.9 |
| Change at Week 9 | 8.2 ± 4.5 | 4.0 ± 7.2 | 1.9 ± 9.8 | 12.8 ± 6.9 |
| Change at Week 13 | 7.3 ± 4.3 | 5.9 ± 6.9 | 5.1 ± 8.9 | 12.9 ± 7.4 |
Criteria for the potential clinical significance included: bilirubin (µmol/L) \>1.5 \* upper limit of normal (ULN), potassium (mmol/L) \>1.2 \* ULN, neutrophils (\*10\^9/L) ≤1, protein (g/L) \>1.1 \* ULN, leukocytes (\*10\^9/L) ≤2.5 or ≥15.
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Bilirubin | 1 | 0 | 0 | 0 |
| Potassium | 2 | 1 | 0 | 1 |
| Neutrophils | 0 | 1 | 1 | 0 |
| Protein | 1 | 0 | 0 | 0 |
| Leukocytes | 1 | 0 | 1 | 0 |
An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs were defined as any event that either began or worsened after the first administration of study drug and within 28 days of the last dose. A summary of other nonserious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Number of Participants With TEAEs | 16 | 6 | 3 | 5 |
Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A + E (Participants on HD): Roxadustat Only, No Iron | — | 3/24 (12.5%) | 6/24 (25%) |
| Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | — | 1/12 (8.3%) | 4/12 (33.3%) |
| Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | — | 0/12 (0%) | 0/12 (0%) |
| Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | — | 3/12 (25%) | 2/12 (16.7%) |
| Event | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| Chemical peritonitisInjury, poisoning and procedural complications | 0/24 | 0/12 | 0/12 | 2/12 |
| Cardiac failure acuteCardiac disorders | 0/24 | 0/12 | 0/12 | 1/12 |
| Device related infectionInfections and infestations | 0/24 | 1/12 | 0/12 | 0/12 |
| Arteriovenous fistula thrombosisInjury, poisoning and procedural complications | 1/24 | 1/12 | 0/12 | 0/12 |
| Cardiac failure chronicCardiac disorders | 1/24 | 0/12 | 0/12 | 0/12 |
| Myocardial infarctionCardiac disorders | 1/24 | 0/12 | 0/12 | 0/12 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/24 | 0/12 | 0/12 | 0/12 |
| Pyelonephritis chronicInfections and infestations | 1/24 | 0/12 | 0/12 | 0/12 |
| Event | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg |
|---|---|---|---|---|
| HypertensionVascular disorders | 1/24 | 3/12 | 0/12 | 2/12 |
| Transferrin saturation decreasedInvestigations | 3/24 | 1/12 | 0/12 | 0/12 |
| PhlebitisVascular disorders | 2/24 | 1/12 | 0/12 | 0/12 |
Safety population included all participants who received any dose of study drug.
| Age, Continuous(years) | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Total |
|---|---|---|---|---|---|
| Mean | 49.6 ± 17.7 | 46.8 ± 14.6 | 53.1 ± 12.6 | 51.4 ± 12.4 | 50.1 ± 15.0 |
| Sex: Female, Male(Participants) | Arm A + E (Participants on HD): Roxadustat Only, No Iron | Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg | Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg | Total |
|---|---|---|---|---|---|
| Female | 9 | 3 | 7 | 10 | 29 |
| Male | 15 | 9 | 5 | 2 | 31 |
Ran from Jul 2011 to primary completion in Jan 2013, 17 months.
Results were first posted in Oct 2021, 8 years 8 months after primary completion.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 17 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roxadustat